Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Express Scripts
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FIRMAGON

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Firmagon

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00451958 A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy Completed Ferring Pharmaceuticals Phase 3 2007-03-01 Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.
NCT00801242 Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer Completed Ferring Pharmaceuticals Phase 3 2008-12-01 The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.
NCT00833248 Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer Completed Ferring Pharmaceuticals Phase 3 2009-04-01 The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months.
NCT00884273 Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients Completed Ferring Pharmaceuticals Phase 3 2009-08-01 This was a Phase 3b clinical study in prostate cancer patients which aimed to compare the current standard therapy of a gonadotrophin releasing hormone (GnRH) agonist, goserelin (3.6 mg; plus anti-androgen flare protection, bicalutamide), to a novel GnRH antagonist, degarelix (240 mg starting dose/80 mg maintenance dose) with respect to mean percentage reduction in prostate volume. The hypothesis was that degarelix could decrease prostate size at least as effectively as the combination of a GnRH agonist with an anti-androgen for flare protection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Firmagon

Condition Name

Condition Name for Firmagon
Intervention Trials
Prostate Cancer 21
Stage IV Prostate Cancer 4
Stage III Prostate Cancer 4
Prostatic Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Firmagon
Intervention Trials
Prostatic Neoplasms 36
Adenocarcinoma 8
Cardiovascular Diseases 2
Breast Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Firmagon

Trials by Country

Trials by Country for Firmagon
Location Trials
United States 106
Canada 24
Germany 7
United Kingdom 6
Italy 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Firmagon
Location Trials
Texas 8
Colorado 7
California 7
New York 7
Florida 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Firmagon

Clinical Trial Phase

Clinical Trial Phase for Firmagon
Clinical Trial Phase Trials
Phase 4 3
Phase 3 14
Phase 2 15
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Firmagon
Clinical Trial Phase Trials
Recruiting 16
Completed 12
Active, not recruiting 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Firmagon

Sponsor Name

Sponsor Name for Firmagon
Sponsor Trials
Ferring Pharmaceuticals 22
National Cancer Institute (NCI) 5
Sidney Kimmel Comprehensive Cancer Center 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Firmagon
Sponsor Trials
Other 42
Industry 28
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
McKesson
Johnson and Johnson
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.